<DOC>
	<DOCNO>NCT01098331</DOCNO>
	<brief_summary>RATIONALE : Receiving standard information watch video DVD home describes treatment option treatment outcome may help patient decide receive treatment clinical trial . PURPOSE : This randomized clinical trial study implant radiation therapy see well work compare surgery treat patient prostate cancer .</brief_summary>
	<brief_title>Implant Radiation Therapy Surgery Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine proportion patient consent treatment randomization brachytherapy vs radical prostatectomy treat patient good-risk prostate cancer . - Determine feasibility randomization , term average accrual rate per center , last 6 month recruitment . Secondary - Determine decisional quality post-treatment patient . - Determine compliance allocate treatment patient . - Determine clinical failure patient . - Determine PSA relapse patient . - Determine patient-reported quality life . - Compare toxicity regimen . OUTLINE : This multicenter study . - Part 1 ( decision-aid randomization ) : Patients stratify accord participate center . Patients randomize 1 2 Decision-Aid arm . - Arm I ( standard patient information ) : Patients receive standard patient information accord routine clinical practice preferred material center . This information typically include booklet prostate cancer treatment , contact detail source information ( e.g. , prostate support group , prostate charity , web-based information ) , access specialist nurse require . - Arm II ( standard patient information + decision aid ) : In addition standard information describe Arm I , patient give 30-minute Decision-Aid video DVD take home . The Decision Aid describe standard treatment option available patient , provide detailed information treatment outcomes relation individual patient characteristic , seek help patient apply personal value treatment decision . Patients may watch audio-visual aid many time wish . Patients decide choose treatment remove study ; patient agree undergo treatment randomization proceed part 2 study . - Part 2 ( treatment randomization ) : Patients stratify accord risk ( low risk v intermediate risk ) . Patients randomize 1 2 treatment arm . - Arm I ( radical prostatectomy ) : Patients undergo surgery within 60 day randomization . The surgical technique radical prostatectomy may retropubic , transperineal , laparoscopic robotic . Pelvic lymph node surgery permit discretion treat surgeon . Unilateral bilateral nerve-sparing technique may use discretion treat surgeon . - Arm II ( brachytherapy ) : Patients undergo brachytherapy within 60 day randomization . Brachytherapy seed may implant use pre-loaded needle MICK® applicator either iodine I 125 palladium Pd 103 . Patient-reported quality-of-life data collect ass erectile function , urinary function , bowel function , general quality life baseline follow . Patients follow 1 4 month , every 4 month 2 year , every 6 month 3 year , annually 5 year . Peer Reviewed Funded Endorsed Cancer Research UK</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meeting 1 follow criterion : Prostate cancer suspect prostate cancer confine prostate ( DecisionAid Randomization ) Clinical stage T1/T2 Due prostate biopsy prostate biopsy perform last 6 week PSA &lt; 15 ng/mL Histologically confirm prostate cancer ( Treatment Randomization ) Clinical stage T1/T2 Rebiopsy period active surveillance discretion treat investigator Must meet 1 follow risk criterion ( PSA test &lt; 3 month prior treatment intervention ) : Low risk : Gleason score ≤ 6 ( tertiary grade 4 5 ) PSA &lt; 10 ng/mL Intermediate risk : Gleason score 3 + 4 ( tertiary grade 5 ) PSA &gt; 10 ng/mL ≤ 15 ng/mL Transrectal ultrasound prostate volume ≤ 50 cc PATIENT CHARACTERISTICS : WHO performance status 01 Life expectancy &gt; 10 year ( DecisionAid Randomization ) Satisfactory result biochemical hematological profile , opinion investigator , preclude patient trial No unacceptable risk radical prostatectomy prostate brachytherapy INR &lt; 1.5 No severe low urinary tract symptoms No significant obstructive urinary symptom ( i.e. , peak urine flow rate &lt; 10 mL per second , and/or post micturition bladder volume &gt; 100 mL ) No clinical medical condition , opinion investigator , precludes patient take part trial No active malignancy likely interfere subsequent protocol treatment followup PRIOR CONCURRENT THERAPY : No prior pelvic radiotherapy No prior abdominoperineal ( AP ) rectal excision No prior standard transurethral resection prostate No prior concurrent neoadjuvant adjuvant hormonal treatment , ( e.g. , LHRH agonists , antiandrogens estrogen ) At least 5 day since prior aspirin clopidogrel No concurrent warfarin</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>